This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSCI COSCIENS Biopharma (CSCI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesTrendsBuy This Stock About COSCIENS Biopharma Stock (NASDAQ:CSCI) Get COSCIENS Biopharma alerts:Sign Up Key Stats Today's Range$2.72▼$2.7250-Day Range$2.61▼$3.9552-Week Range$2.50▼$4.40VolumeN/AAverage Volume7,571 shsMarket Capitalization$8.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. Read More Receive CSCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COSCIENS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSCI Stock News HeadlinesCOSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEOJune 18 at 8:51 AM | financialpost.comFCOSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEOJune 18 at 8:30 AM | globenewswire.comHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.June 18 at 1:00 AM | InvestPub (Ad)CSCI Leverages Technology, Workforce Expansion, and Operational Discipline to Drive Continued Growth Across FloridaJune 11, 2026 | businesswire.comCOSCIENS Biopharma Inc. Reports Q1 2026 ResultsMay 12, 2026 | financialpost.comFCOSCIENS Biopharma Inc. Reports Q1 2026 ResultsMay 12, 2026 | globenewswire.comCOSCIENS Biopharma Sets June 17, 2026 Virtual Annual and Special Shareholder MeetingMay 8, 2026 | tipranks.comCOSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting ObligationsApril 20, 2026 | markets.businessinsider.comSee More Headlines CSCI Stock Analysis - Frequently Asked Questions How were COSCIENS Biopharma's earnings last quarter? COSCIENS Biopharma Inc. (NASDAQ:CSCI) posted its earnings results on Thursday, August, 14th. The company reported ($0.85) EPS for the quarter. The company had revenue of $2.75 million for the quarter. COSCIENS Biopharma had a negative net margin of 199.55% and a negative trailing twelve-month return on equity of 149.49%. What other stocks do shareholders of COSCIENS Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings8/14/2025Today6/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CSCI CIK1113423 Webwww.cosciensbio.com Phone49-6942-6020Fax418-948-9191Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.31 million Net Margins-199.55% Pretax Margin-189.27% Return on Equity-149.49% Return on Assets-54.80% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.65 Sales & Book Value Annual Sales$9.44 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.78Miscellaneous Outstanding Shares3,176,000Free Float3,173,000Market Cap$8.64 million OptionableN/A Beta0.91 Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CSCI) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHopeless About Retirement? Hopeless and Helpless Aren’t the Same ThingYour retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...Golden Portfolio | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredDo NOT buy or sell SPCX before reading thisSpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredTesla's robot factory goes live this summerOn Tesla's Q1 2026 earnings call, Elon Musk confirmed Optimus robot production at the Fremont factory begins l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
